Pfizer has slashed its sales estimates for COVID antiviral Paxlovid by $7 billion and its COVID vaccine Comirnaty by $2 billion. It adds up to a 13% decline in projected revenue for the company in 2023. As the coronavirus outbreak has shifted to the endemic phase, drugmakers have warned of a drop in demand for COVID-19 products, with the impact coming into focus during the fall vaccination season. Pfizer has stepped up to the plate with an update, and its effects are staggering as the company has slashed its 2023 revenue projection by $9 billion. Pfizer now expects sales to...
